Rosen Law Firm Files Class Action Against ImmunityBio
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 16 hours ago
0mins
Should l Buy IBRX?
Source: PRnewswire
- Class Action Initiated: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased ImmunityBio securities between January 19 and March 24, 2026, alleging that the company made false and misleading statements during this period, potentially leading to investor losses.
- Compensation Mechanism: Investors participating in the class action may receive compensation without any out-of-pocket costs, indicating a risk-free remedy for affected investors and enhancing their confidence in pursuing legal action.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and experience in handling similar cases.
- Details of Allegations: The lawsuit claims that ImmunityBio executives materially overstated Anktiva's capabilities, leading to investor misunderstandings about the company's business prospects, reflecting potential governance and transparency issues within the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.670
Low
5.00
Averages
7.33
High
9.00
Current: 7.670
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio's Global Expansion and Balance Sheet Strengthening
- Balance Sheet Strengthening: Founder Patrick Soon-Shiong indicated plans to strengthen the balance sheet and prepare for global expansion, despite recent stock price impacts from an FDA warning letter, the company is focused on achieving long-term growth.
- European Expansion Talks: Soon-Shiong mentioned discussions with a European health minister aimed at advancing 'immunotherapy 2.0', which will help the company promote NK cell and CD8 T-cell-based therapies in new markets, enhancing its competitive position.
- Declining Short Interest: Short interest in IBRX has decreased from 13.7% in mid-February to 12.9%, reflecting increased market confidence in the Anktiva therapy, especially after receiving conditional marketing authorization from the EU.
- FDA Warning Impact: Although the FDA issued a warning regarding Anktiva's promotional claims, leading to a short-term stock drop, the company is actively advancing clinical trials for new indications, demonstrating resilience and potential in the market.
See More
Rosen Law Firm Files Class Action Against ImmunityBio
- Class Action Initiated: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased ImmunityBio securities between January 19 and March 24, 2026, alleging that the company made false and misleading statements during this period, potentially leading to investor losses.
- Compensation Mechanism: Investors participating in the class action may receive compensation without any out-of-pocket costs, indicating a risk-free remedy for affected investors and enhancing their confidence in pursuing legal action.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and experience in handling similar cases.
- Details of Allegations: The lawsuit claims that ImmunityBio executives materially overstated Anktiva's capabilities, leading to investor misunderstandings about the company's business prospects, reflecting potential governance and transparency issues within the company.
See More
Class Action Lawsuit Filed Against ImmunityBio, Inc.
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of ImmunityBio, Inc. (NASDAQ: IBRX) securities from January 19 to March 24, 2026, alleging that the company made false and misleading statements during this period, resulting in investor losses.
- Compensation Mechanism: Investors participating in the lawsuit may be entitled to compensation without any out-of-pocket fees, indicating a risk-free legal remedy for victims and potentially attracting more investors to join the action.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and experience in handling such cases.
- Details of Allegations: The lawsuit claims that ImmunityBio's executive Patrick Soon-Shiong materially overstated Anktiva's capabilities, leading to reputational damage for the company and financial losses for investors when the truth emerged, highlighting concerns over corporate governance and transparency.
See More
ImmunityBio Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ImmunityBio, aiming to recover damages for investors who purchased the company's securities between January 19, 2026, and March 24, 2026, highlighting concerns over potential investor losses.
- False Statement Allegations: The complaint alleges that ImmunityBio's executive Soon-Shion materially overstated Anktiva's capabilities, resulting in materially false and misleading statements regarding the company's business and prospects, which could significantly impact investor decisions.
- Investor Participation Opportunity: Affected investors have until May 26, 2026, to request to be appointed as lead plaintiff, indicating that the lawsuit provides an opportunity for investors to participate in claims without needing to serve as lead plaintiff.
- No-Risk Legal Services: Bronstein, Gewirtz & Grossman, LLC offers contingency fee-based legal services, meaning they will only charge fees if successful in recovering damages, ensuring financial safety for investors pursuing their losses.
See More
ImmunityBio's Anktiva Receives EU Approval, Boosting Stock
- Anktiva Approval: ImmunityBio (IBRX) received conditional marketing authorization for Anktiva across 33 countries, boosting its market valuation to nearly $6.9 billion with a 287% stock price increase, highlighting its strong growth potential in cancer treatment.
- Adlai Nortye Clinical Progress: Adlai Nortye (ANL) dosed its first U.S. patient in the global AN9025 trial, leading to a 387% stock price surge and a market cap of $216.16 million, indicating significant advancements in its oncology strategy.
- Erasca Global Strategy: Erasca (ERAS) secured worldwide rights to ERAS-0015, resulting in a 335% stock price increase and a market cap exceeding $4.6 billion, reflecting its potential in cancer drug development with promising early clinical responses.
- Investor Sentiment Fluctuations: While IBRX experienced volatile investor sentiment, ANL's shifted from extremely bullish to neutral, and ERAS remained bearish, yet overall interest in these biotech firms increased, indicating sustained market engagement.
See More
ImmunityBio Investors Reminder for Class Action Lawsuit
- Lawsuit Deadline: Investors must file Lead Plaintiff applications by May 26, 2026, if they purchased ImmunityBio securities between January 19 and March 24, 2026, indicating the legal risks and potential liabilities the company faces.
- FDA Warning Letter Impact: On March 24, 2026, the FDA issued a warning letter to CEO Richard Adcock, stating that misleading claims in advertisements about Anktiva led to a 21% drop in share price, losing $1.98 per share, reflecting market concerns over the company's compliance.
- Legal Allegations Context: ImmunityBio and its executives are accused of failing to disclose material information during the class period, violating federal securities laws, which could expose investors to economic losses and further damage the company's reputation and market trust.
- Law Firm's Role: Kahn Swick & Foti, LLC, as the plaintiff law firm, reminds investors of their rights in the securities class action, showcasing the firm's expertise and influence in securities litigation, potentially providing legal support and recovery opportunities for investors.
See More
ImmunityBio's Global Expansion and Balance Sheet Strengthening
- Balance Sheet Strengthening: Founder Patrick Soon-Shiong indicated plans to strengthen the balance sheet and prepare for global expansion, despite recent stock price impacts from an FDA warning letter, the company is focused on achieving long-term growth.
- European Expansion Talks: Soon-Shiong mentioned discussions with a European health minister aimed at advancing 'immunotherapy 2.0', which will help the company promote NK cell and CD8 T-cell-based therapies in new markets, enhancing its competitive position.
- Declining Short Interest: Short interest in IBRX has decreased from 13.7% in mid-February to 12.9%, reflecting increased market confidence in the Anktiva therapy, especially after receiving conditional marketing authorization from the EU.
- FDA Warning Impact: Although the FDA issued a warning regarding Anktiva's promotional claims, leading to a short-term stock drop, the company is actively advancing clinical trials for new indications, demonstrating resilience and potential in the market.
See More
Rosen Law Firm Files Class Action Against ImmunityBio
- Class Action Initiated: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased ImmunityBio securities between January 19 and March 24, 2026, alleging that the company made false and misleading statements during this period, potentially leading to investor losses.
- Compensation Mechanism: Investors participating in the class action may receive compensation without any out-of-pocket costs, indicating a risk-free remedy for affected investors and enhancing their confidence in pursuing legal action.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and experience in handling similar cases.
- Details of Allegations: The lawsuit claims that ImmunityBio executives materially overstated Anktiva's capabilities, leading to investor misunderstandings about the company's business prospects, reflecting potential governance and transparency issues within the company.
See More
Class Action Lawsuit Filed Against ImmunityBio, Inc.
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of ImmunityBio, Inc. (NASDAQ: IBRX) securities from January 19 to March 24, 2026, alleging that the company made false and misleading statements during this period, resulting in investor losses.
- Compensation Mechanism: Investors participating in the lawsuit may be entitled to compensation without any out-of-pocket fees, indicating a risk-free legal remedy for victims and potentially attracting more investors to join the action.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and experience in handling such cases.
- Details of Allegations: The lawsuit claims that ImmunityBio's executive Patrick Soon-Shiong materially overstated Anktiva's capabilities, leading to reputational damage for the company and financial losses for investors when the truth emerged, highlighting concerns over corporate governance and transparency.
See More
ImmunityBio Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ImmunityBio, aiming to recover damages for investors who purchased the company's securities between January 19, 2026, and March 24, 2026, highlighting concerns over potential investor losses.
- False Statement Allegations: The complaint alleges that ImmunityBio's executive Soon-Shion materially overstated Anktiva's capabilities, resulting in materially false and misleading statements regarding the company's business and prospects, which could significantly impact investor decisions.
- Investor Participation Opportunity: Affected investors have until May 26, 2026, to request to be appointed as lead plaintiff, indicating that the lawsuit provides an opportunity for investors to participate in claims without needing to serve as lead plaintiff.
- No-Risk Legal Services: Bronstein, Gewirtz & Grossman, LLC offers contingency fee-based legal services, meaning they will only charge fees if successful in recovering damages, ensuring financial safety for investors pursuing their losses.
See More
ImmunityBio's Anktiva Receives EU Approval, Boosting Stock
- Anktiva Approval: ImmunityBio (IBRX) received conditional marketing authorization for Anktiva across 33 countries, boosting its market valuation to nearly $6.9 billion with a 287% stock price increase, highlighting its strong growth potential in cancer treatment.
- Adlai Nortye Clinical Progress: Adlai Nortye (ANL) dosed its first U.S. patient in the global AN9025 trial, leading to a 387% stock price surge and a market cap of $216.16 million, indicating significant advancements in its oncology strategy.
- Erasca Global Strategy: Erasca (ERAS) secured worldwide rights to ERAS-0015, resulting in a 335% stock price increase and a market cap exceeding $4.6 billion, reflecting its potential in cancer drug development with promising early clinical responses.
- Investor Sentiment Fluctuations: While IBRX experienced volatile investor sentiment, ANL's shifted from extremely bullish to neutral, and ERAS remained bearish, yet overall interest in these biotech firms increased, indicating sustained market engagement.
See More
ImmunityBio Investors Reminder for Class Action Lawsuit
- Lawsuit Deadline: Investors must file Lead Plaintiff applications by May 26, 2026, if they purchased ImmunityBio securities between January 19 and March 24, 2026, indicating the legal risks and potential liabilities the company faces.
- FDA Warning Letter Impact: On March 24, 2026, the FDA issued a warning letter to CEO Richard Adcock, stating that misleading claims in advertisements about Anktiva led to a 21% drop in share price, losing $1.98 per share, reflecting market concerns over the company's compliance.
- Legal Allegations Context: ImmunityBio and its executives are accused of failing to disclose material information during the class period, violating federal securities laws, which could expose investors to economic losses and further damage the company's reputation and market trust.
- Law Firm's Role: Kahn Swick & Foti, LLC, as the plaintiff law firm, reminds investors of their rights in the securities class action, showcasing the firm's expertise and influence in securities litigation, potentially providing legal support and recovery opportunities for investors.
See More
